NewAmsterdam Pharma Co N.V. Income Tax Expense (Benefit) in USD from 2023 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
NewAmsterdam Pharma Co N.V. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2023 to 2024.
  • NewAmsterdam Pharma Co N.V. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was -$1K.
  • NewAmsterdam Pharma Co N.V. annual Income Tax Expense (Benefit) for 2024 was -$1K, a 104% decline from 2023.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

NewAmsterdam Pharma Co N.V. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$1K Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05

NewAmsterdam Pharma Co N.V. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$1K -$28K -104% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-26
2023 $27K Jan 1, 2023 Dec 31, 2023 10-K 2025-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.